Trial · NCT07913152
Heart@Home Safety and Efficacy of Hospital-at-Home Care Versus Standard Hospitalization in Cardiac Patients
NCT07913152, Not applicable, Recruiting, Tel-Aviv Sourasky Medical Center
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Heart@Home Safety and Efficacy of Hospital-at-Home Care Versus Standard Hospitalization in Cardiac Patients. Trials, record NCT07913152. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07913152
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Heart@Home Safety and Efficacy of Hospital-at-Home Care Versus Standard Hospitalization in Cardiac Patients
- NCT number
- NCT07913152
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 150 participants, estimated
- Lead sponsor
- Tel-Aviv Sourasky Medical Center
- Conditions
- Myocardial Infarction, Myocarditis Acute, Pericarditis, Pulmonary Embolism Acute, Heart Failure Acute, Transcatheter Valve Replacement, Defibrillators, Implantable
- Interventions
- Remote cardiovascular monitoring at home
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Composite Primary Safety Outcomes number of Events | 1. Through hospitalization completion, an expected average of 3-5 days 2. Re-hospitalization and all-cause mortality at 30 days following discharge | The total number of events - Each of the following events will be contented is 1 unit: including all-cause mortality during hospitalization; Hospital-acquired infections; Hemodynamic deterioration requiring inotropic treatment and/or mechanical ventilation; Acute kidney injury according to KDIGO criteria; Deep vein thrombosis and/or pulmonary embolism; Medication administration errors; Hospital readmission within 30 days; and All-cause mortality within 30 days. |
| Primary | Patient Experience Questionnaire | Questionnaire filled at the day of discharge from admission, an average of 3-5 days, and refers to the hospitalization duration. | The total score of the 15-item Picker Patient Experience Questionnaire. |
| Secondary | Composite Secondary Endpoints number of Events | 1. Through hospitalization completion, an expected average of 3-5 days 2. Re-hospitalization and all-cause mortality at 30 days following discharge | Duration of hospitalization; Number of diagnostic tests performed during hospitalization, including laboratory tests, imaging examinations, Holter monitoring, and specialist consultations; Number and duration of intravenous treatments; Number of hours of oxygen treatment per day; Episodes of peripheral intravenous-line phlebitis; Episodes of venous thromboembolism; Episodes of acute kidney injury; Requirement for urinary catheterization; Medication administration errors; Falls; Mobility and number of active hours per day measured by continuous monitoring; Daily step count; Hours of sleep per day; Cardiac arrhythmias, including atrial fibrillation, atrial flutter, ventricular tachycardia, and second-degree or higher atrioventricular conduction abnormalities; Requirement for transfer from H@H to conventional hospital care; Number of daily nursing visits; Number of daily cardiologist assessments; Cardiac and all-cause hospital readmission within 30 days; All-cause mortality at 30 days; |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07913152
GET https://conductscience.org/api/trials/v1/NCT07913152/registered